Usnarska-Zubkiewicz Lidia, Strutyńska-Karpińska Marta, Zubkiewicz-Kucharska Agnieszka, Zarębski Paweł, Grabowski Krzysztof
Department of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
Department of Gastrointestinal and General Surgery, Wroclaw Medical University, Poland.
Adv Clin Exp Med. 2014 Nov-Dec;23(6):959-67. doi: 10.17219/acem/30817.
The urokinase plasminogen activation system is associated with metastatic potential of cancer in several tumors. Its specific membrane receptor (uPAR) is released from cancer cells and can be detected as the soluble fraction of the plasminogen activator receptor (suPAR). Ferritin (FRT) is a poor prognostic factor in various neoplasms.
We analyzed the serum concentrations of suPAR and FRT in patients with gastrointestinal cancer. Tumor localization, stage of the disease, possibility of surgery and histopathological diagnosis were considered.
The analysis involved 48 patients (8 females/40 males) treated in the Department of Gastrointestinal and General Surgery, Wroclaw Medical University. Thirty two patients had esophageal, 7-gastric, 9-colorectal cancer. Fifteen patients underwent resection surgery, 33 palliative therapy. The control comprised 10 healthy donors. The serum concentration of suPAR was determined by enzyme-linked immunosorbent assay (ELISA), expressed in pg/mL. Concentration of the serum FRT was detected using immunonephelometry method, expressed in µg/L.
Serum concentration of suPAR ranged from 1789-7320, x=3676.2, SD=1042 and was significantly higher (p=0.0002) than in the control group. In patients who underwent palliative therapy, the concentration of suPAR was significantly higher (p=0.05) than in those after resection, also in patients with esophageal cancer compared to those with colorectal one (p=0.02). Serum concentration of FRT in patients with gastrointestinal cancer was significantly higher than in control group. Serum FRT concentration was higher in patients with esophageal cancer compared to patients with gastric cancer (p=0.05), in persons with IV compared to patients with I-III stage of the disease, patients who underwent palliative compared to surgical therapy.
In patients with gastrointestinal cancer the level of suPAR is high, with highest values in advances disease with remote metastases. The FRT concentration is sensitive indicator of the disease process: its level is highest in pts with IV stage who underwent palliative therapy.
尿激酶纤溶酶原激活系统与多种肿瘤的癌症转移潜能相关。其特异性膜受体(uPAR)从癌细胞中释放出来,可作为纤溶酶原激活物受体的可溶性部分(suPAR)被检测到。铁蛋白(FRT)在各种肿瘤中是一个不良预后因素。
我们分析了胃肠道癌患者血清中suPAR和FRT的浓度。考虑了肿瘤定位、疾病分期、手术可能性和组织病理学诊断。
分析涉及弗罗茨瓦夫医科大学胃肠与普通外科治疗的48例患者(8名女性/40名男性)。32例患有食管癌,7例患有胃癌,9例患有结直肠癌。15例患者接受了切除手术,33例接受了姑息治疗。对照组包括10名健康供者。采用酶联免疫吸附测定法(ELISA)测定血清suPAR浓度,以pg/mL表示。采用免疫比浊法检测血清FRT浓度,以µg/L表示。
血清suPAR浓度范围为1789 - 7320,x = 3676.2,标准差 = 1042,显著高于对照组(p = 0.0002)。接受姑息治疗的患者中,suPAR浓度显著高于切除术后患者(p = 0.05),食管癌患者的suPAR浓度也高于结直肠癌患者(p = 0.02)。胃肠道癌患者血清FRT浓度显著高于对照组。食管癌患者的血清FRT浓度高于胃癌患者(p = 0.05),IV期患者高于I - III期患者,接受姑息治疗的患者高于接受手术治疗的患者。
胃肠道癌患者的suPAR水平较高,在伴有远处转移的晚期疾病中值最高。FRT浓度是疾病进程的敏感指标:其水平在接受姑息治疗的IV期患者中最高。